This podcast reports on a phase I/II trial investigating novel anti-CD22, moxetumomab pasudotox, in the treatment of patients with refractory hairy cell leukemia, which demonstrated responses in the majority of patients at all dose levels.
What you need to know about GIVETAXFREE.ORG
Share
givetaxfree.org
The Rich Get Richer: Another Efficacious Option for Refractory Hairy Cell Leukemia [Video]
Categories
This is GIVETAXFREE.ORG! Start your campaign now! ✨
Share
givetaxfree.org
![16. Acute Myeloid Leukemia | USMLE Step 1 Pathology [Video]](https://crowd-funding.givetaxfree.org/wp-content/uploads/2024/04/mp_259094_0_0jpg.jpg)
![Hope is a promise to all patients (Northern Virginia) [Video]](https://crowd-funding.givetaxfree.org/wp-content/uploads/2024/04/mp_258827_0_0jpg.jpg)
![Snooker star feared for his life after terrifying cancer diagnosis but is now fighting for World Championship [Video]](https://crowd-funding.givetaxfree.org/wp-content/uploads/2024/04/mp_256729_0_crop27509226jpg.jpg)
![Young-onset colorectal cancer survivor: Get your symptoms checked [Video]](https://crowd-funding.givetaxfree.org/wp-content/uploads/2024/04/mp_256813_0_0jpg.jpg)
